{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:46:40Z","timestamp":1790657200855,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003562","name":"Ministry of Environment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.coi.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T18:06:08Z","timestamp":1586801168000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Recent advances in atopic dermatitis"],"prefix":"10.1016","volume":"66","author":[{"given":"Kangmo","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Eui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald YM","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2020.02.007_sbref0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav2685","article-title":"The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype","volume":"11","author":"Leung","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2020.02.007_sbref0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1172\/JCI124608","article-title":"Epithelial barrier repair and prevention of allergy","volume":"129","author":"Goleva","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2020.02.007_bib0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: clinical implications","volume":"40","author":"Kim","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.coi.2020.02.007_sbref0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.anai.2019.01.003","article-title":"The microbiome and allergic diseases: a struggle between good and bad microbes","volume":"122","author":"Leung","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0025","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaad.2018.05.1241","article-title":"A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0030","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaad.2018.08.063","article-title":"Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis","volume":"80","author":"Patel","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0040","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jaci.2018.11.030","article-title":"Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies","volume":"143","author":"Ascott","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jid.2018.10.029","article-title":"Racial\/ethnic differences in incidence and persistence of childhood atopic dermatitis","volume":"139","author":"Kim","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2019.07.048","article-title":"Environmental factors associated with allergy in urban and rural children from the South African Food Allergy (SAFFA) cohort","volume":"145","author":"Levin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0055","article-title":"Mental health impairment among children with atopic dermatitis: a U.S. population-based cross-sectional study of the 2013-2017 National Health Interview Survey","author":"Wan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0060","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.anai.2019.09.008","article-title":"Association of atopic dermatitis with increased risk of anaphylaxis to egg and milk","volume":"123","author":"Hoffman","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.anai.2019.05.014","article-title":"The prevalence and persistence of atopic dermatitis in urban United States children","volume":"123","author":"McKenzie","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0070","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/all.13320","article-title":"The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies","volume":"73","author":"Abuabara","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.coi.2020.02.007_bib0075","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jaip.2019.10.007","article-title":"The association between season of birth and atopic dermatitis in the Northern hemisphere: a systematic review and meta-analysis","volume":"8","author":"Calov","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.coi.2020.02.007_bib0080","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jid.2018.08.035","article-title":"Are environmental factors for atopic eczema in ISAAC Phase Three due to reverse causation?","volume":"139","author":"Rutter","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/pai.12903","article-title":"Atopic dermatitis: interaction between genetic variants of GSTP1, TNF, TLR2, and TLR4 and air pollution in early life","volume":"29","author":"Huls","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jaci.2018.09.031","article-title":"Nonatopic eczema in elderly women: effect of air pollution and genes","volume":"143","author":"Huls","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/all.13946","article-title":"The exposome in atopic dermatitis","volume":"75","author":"Stefanovic","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.coi.2020.02.007_bib0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of skin barrier dysfunction in atopic dermatitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.coi.2020.02.007_bib0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2019.10.008","article-title":"The role of filaggrin in atopic dermatitis and allergic disease","volume":"124","author":"Drislane","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaci.2019.07.033","article-title":"Epidermal mammalian target of rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formation","volume":"145","author":"Ding","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0115","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaci.2019.05.024","article-title":"EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis","volume":"144","author":"Elias","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0120","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.jid.2019.02.030","article-title":"Keratinocyte proline-rich protein deficiency in atopic dermatitis leads to barrier disruption","volume":"139","author":"Suga","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0125","article-title":"The cornified envelope-bound ceramide fraction is altered in patients with atopic dermatitis","author":"Boiten","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98006","article-title":"Lipid abnormalities in atopic skin are driven by type 2 cytokines","volume":"3","author":"Berdyshev","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2020.02.007_bib0135","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaci.2018.01.019","article-title":"Epidermal lipid compostion, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration","volume":"141","author":"Baurecht","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0140","article-title":"Increased IL-26 expression promotes T helper type 17- and T helper type 2-associated cytokine production by keratinocytes in atopic dermatitis","author":"Kamijo","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jid.2018.08.016","article-title":"IL-10-producing regulatory B cells are decreased in patients with atopic dermatitis","volume":"139","author":"Yoshihara","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0150","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jid.2019.02.006","article-title":"Staphylococcus aureus lipoteichoic acid damages the skin barrier through an IL-1-mediated pathway","volume":"139","author":"Brauweiler","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.02.006","article-title":"Staphylococcus aureus lipoteichoic acid initiates a TSLP-basophil-IL4 axis in the skin","author":"Brauweiler","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0160","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.jid.2019.06.118","article-title":"ILC2s and basophils team up to orchestrate IL-33-induced atopic dermatitis","volume":"139","author":"Ryffel","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0165","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaci.2019.06.011","article-title":"Thymic stromal lymphopoietin epigenetically upregulates Fc receptor gamma subunit-related receptors on antigen-presenting cells and induces TH2\/TH17 polarization through dectin-2","volume":"144","author":"Liang","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaci.2018.11.015","article-title":"The microbiome in patients with atopic dermatitis","volume":"143","author":"Paller","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0175","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaad.2019.08.078","article-title":"The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis","volume":"82","author":"Woo","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","article-title":"IL-4Ralpha blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis","volume":"140","author":"Callewaert","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0185","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jaci.2018.11.036","article-title":"A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor","volume":"143","author":"Yu","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jid.2019.06.142","article-title":"Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides","volume":"140","author":"Smits","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0205","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2019.10.010","article-title":"Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review","volume":"82","author":"Igelman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0220","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0225","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_sbref0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","article-title":"A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis","volume":"80","author":"Peppers","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0240","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0245","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0250","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2020.02.007_bib0260","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2020.02.007_bib0265","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791520300236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791520300236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:43:57Z","timestamp":1760604237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791520300236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":53,"alternative-id":["S0952791520300236"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2020.02.007","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}